We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Chronic pains

22 October 2019 By Dasha Afanasieva

The $54 bln maker of Gaviscon antacid is still having trouble absorbing its 2017 purchase of baby food maker Mead Johnson, says outgoing CFO Adrian Hennah. The result is a second cut in the 2019 sales target. The recognition is welcome, but a full recovery may require more pain.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)